These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7248 related articles for article (PubMed ID: 2458854)

  • 1. Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation.
    Costantini V; Fuschiotti P; Allegrucci M; Agnelli G; Nenci GG; Fioretti MC
    Cancer Chemother Pharmacol; 1988; 22(4):289-93. PubMed ID: 2458854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice.
    Costantini V; Fuschiotti P; Giampietri A; Allegrucci M; Agnelli G; Nenci GG; Fioretti MC
    Prostaglandins; 1990 Jun; 39(6):581-99. PubMed ID: 1695382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimetastatic action of the prostacyclin analog iloprost in the mouse.
    Sava G; Perissin L; Zorzet S; Piccini P; Giraldi T
    Clin Exp Metastasis; 1989; 7(6):671-8. PubMed ID: 2476273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of prostacyclin on tumor cell-induced platelet aggregation.
    Menter DG; Onoda JM; Taylor JD; Honn KV
    Cancer Res; 1984 Feb; 44(2):450-6. PubMed ID: 6362850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.
    Hermán F; Hadházy P; Magyar K
    Arch Int Pharmacodyn Ther; 1989; 300():281-91. PubMed ID: 2482710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of human and animal platelet aggregation by a new prostacyclin analog.
    Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of NK cells in the antimetastatic effect of anticoagulant drugs.
    Gorelik E; Bere WW; Herberman RB
    Int J Cancer; 1984 Jan; 33(1):87-94. PubMed ID: 6363308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation.
    Wadenvik H; Kutti J
    Acta Haematol; 1985; 73(4):224-7. PubMed ID: 2414956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin.
    Honn KV; Cavanaugh P; Evens C; Taylor JD; Sloane BF
    Science; 1982 Aug; 217(4559):540-2. PubMed ID: 7046053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimetastatic action of stable prostacyclin analogs in mice.
    Giraldi T; Rapozzi V; Perissin L; Zorzet S
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():913-6. PubMed ID: 1705086
    [No Abstract]   [Full Text] [Related]  

  • 13. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
    Stürzebecher S; Witt W
    Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
    Kobzar G; Mardla V; Järving I; Samel N
    Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell membrane signaling as target in cancer therapy. II: Inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation.
    Okoshi H; Hakomori S; Nisar M; Zhou QH; Kimura S; Tashiro K; Igarashi Y
    Cancer Res; 1991 Nov; 51(22):6019-24. PubMed ID: 1657377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic profile of iloprost in experimental models of in vivo platelet aggregation and thrombosis.
    Witt W; Müller B
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():279-84. PubMed ID: 2444077
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation.
    Menter DG; Onoda JM; Moilanen D; Sloane BF; Taylor JD; Honn KV
    J Natl Cancer Inst; 1987 May; 78(5):961-9. PubMed ID: 3553692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrillatory action of the stable orally active prostacyclin analogues iloprost and ZK 96 480 in rats after coronary artery ligation.
    Müller B; Maass B; Stürzebecher S; Skuballa W
    Biomed Biochim Acta; 1984; 43(8-9):S175-8. PubMed ID: 6083785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostacyclin, thromboxanes, and hematogenous metastasis.
    Honn KV; Sloane BF
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():313-8. PubMed ID: 6221609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 363.